MCT Oil

The Verdict

MCT oil reliably produces a small ketone bump in your blood. Almost none of the clinical outcomes that bump is supposed to drive convert.

MCT oil is a special class of fats made of shorter carbon chains than the fats in most of your food. They are usually extracted from coconut or palm kernel, then refined. People take them because the liver turns a portion of them into ketones — a backup fuel for the brain — within an hour of swallowing. The pitch is that this lab-detectable ketone bump translates into sharper thinking, faster fat loss, and steadier energy. Think of it like a generator that fires up reliably when you flip the switch. The generator works. What it powers, in most studies, does not turn on.

The verdict: The ketones in your blood go up. The clinical outcomes — cognition in healthy adults, fat loss added to your diet, endurance performance — mostly stay flat in randomized trials. The biomarker moves; the result does not follow.
What most people get wrong: Coconut oil is not MCT oil. About half of coconut oil is lauric acid, which your body absorbs the same way as long-chain fat. A teaspoon of coconut oil in coffee produces almost no ketones. The chemistry says so even when the marketing does not.
Start here: If you want the only protocol the data backs, take roughly one tablespoon — 18 to 24 grams — and use it in place of the olive oil you were already cooking with, inside a calorie-controlled diet for 12 to 16 weeks. Above 30 grams in one sitting you get diarrhea, not benefit.

Best for

Clinician-supervised mild Alzheimer's with APOE4-negative genetic status. Frail older adults on a structured protein and resistance-training plan. Adults intentionally substituting MCT for long-chain fats inside a hypocaloric diet. Anyone with fat-malabsorption requiring an enzyme-independent fat source.

Skip if

You are cognitively normal and want MCT as a nootropic. You are an endurance athlete looking for ergogenic effect. You are adding MCT to your existing diet for fat loss. You bought "MCT" that is mostly coconut oil. You have an undiagnosed metabolic disorder or family history of metabolic crisis.

Want the full evidence? Keep scrolling

The Protocol

Population	Dose	Form	Timing
Weight management — substituting LCT in a hypocaloric diet	18–24 g/d substituted for olive oil or other long-chain fat	C8/C10 blend (standard MCT oil)	With meals
Mild AD APOE4-NEGATIVE — clinician-supervised adjunct	20–40 g/d split 2–3 doses	C8 isolate (caprylidene/Axona-type) preferred	With food
Mild AD APOE4-POSITIVE	NOT INDICATED — does not respond in trials	—	—
Frail elderly with documented sarcopenic risk	6–12 g/d split AM + PM, alongside protein + RT	C8 + C10 emulsified	With protein-containing meals
Acute ketone production (fasted/very-low-CHO context)	15–30 g	C8 isolate	Pre-fast or in-fasted-state
Cognitively normal adult — nootropic claim	NOT SUPPORTED — no positive primary endpoint	—	—
Endurance athlete — ergogenic claim	NOT SUPPORTED — null across 13+ trials with GI distress	—	—
Fat-malabsorption (pancreatic insufficiency, short bowel, CF)	Per RD/clinician dosing	C8/C10 blend or emulsified powder	With each meal
Pediatric refractory epilepsy MCT-KD	30–60% of dietary fat as MCT — RD + neurologist supervised	C8/C10 blend	Per KD protocol
Pregnancy / lactation supplemental dose	NO HUMAN DATA — food-use historically OK	—	—

Forms Comparison

C8/C10 blend (standard MCT oil)

Reference market standard

Cooking, general substitution use. Cheapest credible clinical MCT per gram.

£20–35/month

C8 isolate ("brain octane")

2–3× BHB AUC of blend

Cognitive-claim trial-matching, targeted acute ketonemia. Outcome head-to-head data NONE.

£40–80/month

C8/C10/C12 (with added lauric)

Lower BHB AUC — C12 behaves long-chain

Cooking only. Do NOT expect ketogenic effect. Mis-marketed as MCT.

£15–25/month

Coconut oil

~50% C12 lauric

Cooking. NOT a clinical MCT substitute — minimal ketonemia at consumer doses.

£8–15/month

MCT powder (emulsified)

Carrier-blended

Travel, drink-mixing. Check label — often 30–70% maltodextrin or acacia carrier.

£25–45/month

AC-1202 caprylidene (Axona)

Trial-validated C8 medical food

Mild AD APOE4(-/-) under clinician supervision. FDA-rejected as drug; sold as medical food.

Prescription-grade (US)

Absorption Tips

Take with food unless the goal is acute ketosis on an empty stomach. Spreading 30 grams across a meal sharply reduces GI distress. Start at 5–10 g/d and titrate up over one to two weeks — the GI ceiling is around 30–60 g in one sitting in most adults, and crossing it without titration produces predictable osmotic diarrhea. Coffee mixing does not change the pharmacokinetics meaningfully — it changes adherence. Emulsified MCT powder is often better tolerated than neat oil at matched gram-MCT dose, but verify the powder is not majority maltodextrin or acacia carrier on the supplement facts panel. MCT does not need bile or pancreatic enzymes to absorb — this is the one genuine niche where it is a clinical first-line substrate.

Safety & Interactions

Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) — Absolute contraindication

MCT cannot be β-oxidized in MCADD. Acute hypoglycemia, encephalopathy, and metabolic crisis risk. Usually identified in newborn screening but undiagnosed adult cases exist. If anyone in the family has had unexplained metabolic crisis in infancy, screen first.

Severe hypertriglyceridemia (TG ≥500 mg/dL) — Relative contraindication

MCT can raise TG acutely in some studies. Stabilize first with prescription icosapent ethyl or fibrate where indicated. Not a substitute for prescription EPA in severe HTG.

Baseline LDL-C above target — Caution

Bohl 2021 SR/MA (PMID 34255085) shows MCT modestly raises TC and LDL-C versus unsaturated-fat comparator. Verify lipid panel at 12 weeks on chronic ≥20 g/d use.

Dysphagia or aspiration risk — Caution

Oil aspiration carries lipoid pneumonia risk. Avoid neat MCT in elderly or stroke-rehab patients with documented swallowing impairment. Emulsified powder forms reduce risk.

Anticoagulants (warfarin, DOACs) and antiplatelets — Negligible

No documented bleeding-time effect, unlike fish oil. No specific monitoring required.

Insulin and sulfonylureas in T2D — Mild

Acute ketonemia may modestly improve insulin sensitivity short-term. MCT is not a glycemic medication. Do not adjust diabetes meds based on MCT alone.

Side Effects

Abdominal cramps and bloating in roughly 20–30 percent of users at over 30 g/d single dose. Osmotic diarrhea common at over 30–60 g/d undiluted. Nausea common in initial use. Modest LDL-C/TC rise versus UFA comparator on chronic use. Headache or "keto flu" symptoms reported in low-CHO context, not isolated MCT. Acute hypoglycemia or encephalopathy is rare and pathognomonic for undiagnosed MCADD — discontinue immediately and seek evaluation.

Upper Limit

No formal EFSA, NIH, or IOM Tolerable Upper Intake Level for MCT specifically. Practical GI tolerance ceiling roughly 30–60 g/d single dose; 60–100 g/d total daily with splitting. Doses above 100 g/d only in trained users and with predictable GI cost.

Conviction

MODERATE — endpoint-stratified

Acute ketonemia (plasma BHB rise): HIGH biomarker. Cerebral ketone uptake in MCI: MODERATE biomarker (Cunnane BENEFIC PET). Mild AD APOE4-NEGATIVE cognition: LOW (industry-funded subgroup-rescue). Mild AD APOE4-POSITIVE: DEBUNKED. Healthy-adult cognition: LOW (PMID 35380356 primary NULL). Frail elderly muscle function: EMERGING (Japanese Nisshin OilliO-funded single-region). Weight loss substitution-design: MODERATE direction-only. Weight loss addition-design: DEBUNKED. Postprandial energy expenditure: MODERATE biomarker. Acute satiety: MODERATE. Blood lipids versus UFA: MODERATE NEGATIVE. Endurance ergogenic: DEBUNKED. Pediatric refractory epilepsy MCT-KD: HIGH (clinical-supervised). C8-isolate clinical-outcome advantage over blend: NONE (no head-to-head). Coconut oil as MCT substitute: DEBUNKED.

What would change this

An independent, non-Accera-funded, placebo-controlled, double-blind RCT enrolling 250 or more mild AD patients stratified by APOE4 status, 40 g/d C8 isolate, 12 months, with primary endpoint ADAS-Cog at month 12 (not month 3 or 6 where mid-trial signals tend to emerge and disappear). A 3-point or larger ADAS-Cog advantage over placebo in the APOE4-NEGATIVE arm would upgrade APOE4(-/-) cognition to MODERATE-HIGH. Independent Western replication of the Japanese Nisshin OilliO frail-elderly signal would upgrade frail-elderly to MODERATE. A C8-isolate vs C8/C10-blend head-to-head clinical outcome RCT with cognitive or metabolic primary endpoint would resolve the premium-form-trap question. An addition-design weight-loss RCT — 20–30 g MCT added to habitual diet for 12 weeks, primary endpoint DXA fat mass — would close the substitution-vs-addition question. Predicted null.

Worth Your Money?

Weekly cost (C8/C10 blend)£5–£8 per week at 18–24 g/d — one tablespoon daily substituted for cooking oil

Weekly cost (C8 isolate)£10–£20 per week at 20–30 g/d — the cognitive-claim trial-matched dose

Worth it ifYou have a clinician-confirmed indication: mild AD APOE4-negative under supervision, frail-elderly sarcopenic risk on a structured plan, fat-malabsorption requiring enzyme-independent fats, or you are intentionally substituting MCT for olive oil inside a hypocaloric diet.

Lower priority ifYou are cognitively normal and looking for a nootropic. Your next £30 is better spent on a sleep audit, a structured protein-distribution check across three meals, or a basic vitamin D test if you haven't had one. Resistance training does more for your brain at 50 than any supplement does at 30.

Conditional — narrow clinical use only

Go Deeper

Want to stop wasting money on supplements that don't work? The Verdict reviews one every week — free.

Subscribe — it's free

Sources

Bohl M et al. (2021). Medium-Chain Triglyceride Oil and Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Trials. Adv Nutr. PMID 34255085. SR/MA — modest TC + LDL-C rise vs UFA comparator.
Avgerinos KI / Henderson ST et al. (2020). Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4(-/-): A double-blind randomized controlled crossover trial. Alzheimers Dement (N Y). PMID 31694759. N=87, 26 wk, Accera-funded. Primary ITT NULL; APOE4(-/-) signal at 13 wk.
Marx W et al. (2025). Efficacy and Safety of Exogenous Ketones in People with Mild Neurocognitive Disorder and Alzheimer's Disease: A Systematic Literature Review. PMID 39047293. Mixed signal; APOE4-stratified small short-term effects.
Hu Yang I et al. (2023). Medium-chain fatty acids for the prevention or treatment of Alzheimer's disease: a systematic review and meta-analysis. PMID 36633304. Pooled MD favoring MCT on ADAS-Cog; high heterogeneity.
Norgren J / Sharma A et al. (2022). Impact of medium-chain triglycerides on gait performance and brain metabolic network in healthy older adults: a double-blind, randomized controlled study. PMID 35380356. N=39, 30 g/d 4 wk. Biomarker positive; cognition primary NULL.
Nosaka N et al. (2022). Effects of Timing of Medium-Chain Triglycerides (8:0 and 10:0) Supplementation during the Day on Muscle Mass, Function and Cognition in Frail Elderly Adults. PMID 35122097. Nisshin OilliO-funded; AM dosing marginally favored.
St-Onge MP & Jones PJ (2003). Medium-chain triglycerides increase energy expenditure and decrease adiposity in overweight men. J Nutr. PMID 12634436. +5% EE vs olive oil.
St-Onge MP et al. (2008). Weight-loss diet that includes consumption of medium-chain triacylglycerol oil leads to a greater rate of weight and fat mass loss than does olive oil. Am J Clin Nutr. PMID 18326600. −1.67 kg vs −0.81 kg, 16 wk substitution-design.
St-Onge MP et al. (2017). Coconut oil has less satiating properties than medium chain triglyceride oil. PMID 28689741. C12 lauric ≠ MCT — direct chemistry-vs-marketing.
Misell LM et al. (2001). Chronic medium-chain triacylglycerol consumption and endurance performance in trained runners. J Sports Med Phys Fitness. PMID 11447364. Null on performance; GI distress.
Mumme K & Stonehouse W (2015). Effects of medium-chain triglycerides on weight loss and body composition: a meta-analysis. J Acad Nutr Diet. [cite-unverified] Pooled −0.51 kg substitution-design.
Reger MA et al. (2004). Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. [cite-unverified] Canonical APOE4-stratification landmark; Accera-funded.
Henderson ST et al. (2009). Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease. Nutr Metab (Lond). [cite-unverified] Axona pivotal trial; Accera-funded; FDA-rejected as drug.
Vandenberghe C / Cunnane SC et al. (2017). Tricaprylin alone produces greater and more sustained plasma ketonemia than coconut oil or C8/C10 blends. J Nutr. [cite-unverified] Canonical PK paper; C8 > blend > coconut.
Cunnane SC et al. (2020). Brain ketone uptake and cognition in mild cognitive impairment: BENEFIC trial. [cite-unverified] +230% cerebral ketone uptake on 30 g/d MCT in MCI.
García-García O et al. (2022). The Effects of Medium-Chain Triglyceride Oil Supplementation on Exercise Performance and Substrate Utilization: A Systematic Review. [cite-unverified] Null ergogenic across 13+ trials.
Soltani M et al. (2023). Medium-chain triglycerides (8:0 and 10:0) increase muscle mass and muscle function in frail older individuals. Front Nutr. [cite-unverified] Frail-elderly Nisshin OilliO-funded.
PMID 35470782 (2023). Efficacy of supplemental MCT oil on seizure reduction of adult drug-resistant epilepsy — single-center open-label pilot. N=22, no control.
Zhao W et al. (2024). A randomized feasibility trial of medium chain triglyceride-supplemented ketogenic diet in people with Parkinson's disease. Mov Disord. PMID 38561682.
Han YH et al. (2019). Effects of medium chain triglycerides supplementation on insulin sensitivity and beta cell function: A feasibility study. PMID 31869355.
Dulloo AG et al. (2002). Comparison of diet-induced thermogenesis of foods containing medium- vs long-chain triacylglycerols. PMID 12775122.
Huttenlocher PR (1976). Use of medium-chain triglycerides in epilepsy treatment. [cite-unverified] Canonical pediatric MCT-KD historical reference.

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score

48/100 Low ROI Trust grade C

For fat loss and energy, mostly no. The ketone bump is real; the outcomes you are buying it for mostly do not follow.

Time

Low

Money

Medium

Effort

Low

Risk

Medium

Why this score

C-grade trust for these goals: the ketone bump is well established (Vandenberghe 2017, C8 produces 2 to 3 times the plasma BHB AUC of a blend), but it is a biomarker, and the healthy-adult cognition trial (Norgren/Sharma 2022, PMID 35380356, 30 g/day) was biomarker-positive with a NULL cognition primary endpoint.
Expected benefit for fat loss and energy is small to none: substituting MCT for long-chain fat in a hypocaloric diet yields about minus 0.5 kg pooled (Mumme 2015 meta) to roughly minus 1.67 versus minus 0.81 kg (St-Onge 2008, 16 weeks), adding it on top does nothing, postprandial energy expenditure is only about +5% versus olive oil and acute only (St-Onge 2003), and endurance is null across 13-plus trials.
Time and effort cost are low, a spoonful with meals, but the protocol that works (substitution, not addition) takes more discipline than the coffee ritual people actually follow.
Money cost is Medium and largely unearned for these goals, about $20 to $35 a month for a standard blend and $40 to $80 a month for C8 isolate, and the premium C8 is paying for a pharmacokinetic chart with no outcome head-to-head RCT.
Risk is Medium: GI distress (cramps and osmotic diarrhea) hits about 20 to 30% of users above 30 g in a sitting, MCT modestly raises TC and LDL-C versus an unsaturated-fat comparator (Bohl 2021, PMID 34255085), and there is an absolute contraindication in MCADD.

Why it didn’t score higher

The headline claims (nootropic focus, all-day ketosis, fat loss without dieting) are the ones the evidence specifically falsifies, so for the marketed goal the benefit is near zero.
The fat-loss effect that survives is substitution-only and clinically marginal (under 1 kg over 16 weeks), with the diet doing the work, not the oil.
Coconut oil is roughly 50% C12 lauric acid and behaves like a long-chain fat, so the popular 'coconut oil equals MCT brain fuel' version produces almost no ketones.

Best for

Adults intentionally substituting 18 to 24 g of MCT for long-chain fat inside a hypocaloric weight-loss diet for 12 to 16 weeks (a swap, not an add-on)
Clinician-supervised mild Alzheimer's with APOE4-negative status, as an adjunct, not a self-prescribed nootropic
Frail elderly with documented sarcopenic risk on a protein-and-resistance-training plan, at 6 to 12 g/day
Fat-malabsorption clinical contexts (pancreatic insufficiency, short bowel, biliary disease) where MCT bypasses the bile-and-lipase pathway

Lower ROI if

You add MCT on top of your existing diet for fat loss, which only adds calories with no documented advantage
You are cognitively normal and using it as a nootropic, where every primary cognition endpoint is null
You are an endurance athlete chasing an ergogenic effect, where the result is null across 13-plus trials and the main finding is GI distress
Your baseline LDL-C is above target and you would replace unsaturated fat with MCT, which modestly raises LDL-C

Minimum effective dose

For the only supported consumer goal (substitution-design weight management): 18 to 24 g/day of a C8/C10 blend swapped in for an equal amount of long-chain fat (such as olive oil), taken with meals, built up over 1 to 2 weeks to limit GI distress. There is no effective dose for nootropic, energy, or addition-design fat-loss use; those endpoints are null.

Track this

Body weight and waist over 12 to 16 weeks, remembering the realistic effect is under 1 kg and only on a substitution diet
GI tolerance as you titrate, since cramps and diarrhea above 30 g in a sitting are what end most people's use
A lipid panel at 12 weeks if you use 20 g/day or more chronically, since TC and LDL-C can rise versus unsaturated fat

MCT oil reliably produces a small ketone bump in your blood.

Best for

Skip if

The Protocol

Forms Comparison

Absorption Tips

Safety & Interactions

Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) — Absolute contraindication

Severe hypertriglyceridemia (TG ≥500 mg/dL) — Relative contraindication

Baseline LDL-C above target — Caution

Dysphagia or aspiration risk — Caution

Anticoagulants (warfarin, DOACs) and antiplatelets — Negligible

Insulin and sulfonylureas in T2D — Mild

Side Effects

Upper Limit

Conviction

Worth Your Money?

Sources

Action ROI

Get the complete dosing protocol

Related free research

There are 424 more inside